title: Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy.
abstract: Adequate dosing of interferon (IFN) and its cost-effectiveness for sustained virological response were evaluated in relation to viral load and subtype. Prospective analysis of IFN therapy on 326 patients with chronic hepatitis C free from cirrhosis was performed using 9 or 6 million unit (MU) of IFN for six months daily and/or three times a week. Sustained virological response was achieved in 50-94% of patients with < or =2 x 10(4) copies/ml (competitive RT-PCR) or <100 x 10(3) copies/ml (Amplicor monitor) of HCV RNA by 468-1206 MU of IFN, but response was only 0-25% of the patients with > or =2 x 10(5.5) copies/ml (competitive RT-PCR) or >200 x 10(3) copies/ml (Amplicor monitor), even with 468-1206 MU of IFN. A high sustained rate was demonstrated in patients with 100-200 x 10(3) copies/ml of HCV RNA by 901-1206 MU of IFN, in comparison to that with < or =900 MU of IFN. Multivariate analysis showed that IFN dose had a significant value for the efficacy of IFN therapy in patients presenting 100-200 x 10(3) copies/ml of HCV RNA. Cost efficacy analysis indicated that it cost approximately $10,000, $26,000, and $50,000-227,000 for one person-viral eradication in the patients with <100, 100-200, and >200 x 10(3) copies/ml, respectively. High-dose IFN is only cost effective in patients with intermediate viral loads, and IFN therapy could be recommended in patients with <200 x 10(3) copies/ml of HCV RNA.
authors.affiliation: Department of Internal Medicine (Gastroenterology), University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Shiratori
authors.forename: N
authors.initials: N
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: R
authors.initials: R
authors.lastname: Nakata
authors.forename: M
authors.initials: M
authors.lastname: Ihori
authors.forename: F
authors.initials: F
authors.lastname: Imazeki
authors.forename: O
authors.initials: O
authors.lastname: Yokosuka
authors.forename: T
authors.initials: T
authors.lastname: Kawase
authors.forename: T
authors.initials: T
authors.lastname: Katamoto
authors.forename: T
authors.initials: T
authors.lastname: Unuma
authors.forename: A
authors.initials: A
authors.lastname: Nakamura
authors.forename: F
authors.initials: F
authors.lastname: Ikegami
authors.forename: K
authors.initials: K
authors.lastname: Hirota
authors.forename: M
authors.initials: M
authors.lastname: Omata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D019698:Hepatitis C, Chronic / Q000628:therapy* / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D007372:Interferons